Home › Healthcare › Boston Scientific (NYSE:BSX)

US$3 billion and €4.25 billion of notes priced

Healthcare By Ada Torres 1 min read

Boston Scientific has priced US$3 billion and €4.25 billion of senior notes to help fund its proposed acquisition of Penumbra. The debt carries a range of maturities and includes special redemption terms if the transaction fails to close.

  • US$3 billion across four senior note tranches
  • €4.25 billion across six euro-denominated tranches
  • Proceeds earmarked primarily for the Penumbra acquisition
  • Euro notes fully and unconditionally guaranteed by Boston Scientific
  • Special redemption at 101% if the deal is abandoned or misses its deadline
Boston Scientific Corporation (NYSE:BSX) is lining up a substantial multi-currency debt package for its proposed acquisition of Penumbra, pricing US$3 billion of dollar-denominated senior notes alongside €4.25 billion of euro notes. The offerings are expected to close on 1 December 2026, subject to customary conditions, and are intended to fund the cash component of the transaction as well as related costs.

Bottom Line?

The financing plan gives Boston Scientific a clearer path to the Penumbra deal, but the next test is how the added debt and currency exposure sit alongside the acquisition once both transactions close.

Questions in the middle?

  • Will the Penumbra acquisition complete by the applicable outside date, or will the special mandatory redemption provisions be triggered?
  • What will Boston Scientific's leverage and liquidity look like after the debt is issued and the acquisition is funded?
  • How will the company manage the longer-dated euro debt, including the floating-rate tranche and currency exposure?

Sources